[go: up one dir, main page]

FI20165814A - INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY - Google Patents

INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY

Info

Publication number
FI20165814A
FI20165814A FI20165814A FI20165814A FI20165814A FI 20165814 A FI20165814 A FI 20165814A FI 20165814 A FI20165814 A FI 20165814A FI 20165814 A FI20165814 A FI 20165814A FI 20165814 A FI20165814 A FI 20165814A
Authority
FI
Finland
Prior art keywords
interleukin
prognostic
oncolytic
proudic
biomarker
Prior art date
Application number
FI20165814A
Other languages
Finnish (fi)
Swedish (sv)
Inventor
Kristian Taipale
Akseli Hemminki
Original Assignee
Tilt Biotherapeutics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilt Biotherapeutics Oy filed Critical Tilt Biotherapeutics Oy
Priority to FI20165814A priority Critical patent/FI20165814A/en
Priority to PCT/FI2017/050742 priority patent/WO2018078220A1/en
Publication of FI20165814A publication Critical patent/FI20165814A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an oncolytic viral vector comprising a nucleic acid sequence encoding an anti-interleukin 8 neutralizing antibody.Further, the present invention relates to use of interleukin 8 as a prognostic and predictive biomarkerin oncolytic immunotherapy. In this respect, the present invention is directed to a method ofanalysing whether a subject suffering from a cancer is responsive or non-responsive to the treatment with an oncolytic viral vectorand to a method of monitoringefficacy of an oncolytic immunotherapy.
FI20165814A 2016-10-27 2016-10-27 INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY FI20165814A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20165814A FI20165814A (en) 2016-10-27 2016-10-27 INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY
PCT/FI2017/050742 WO2018078220A1 (en) 2016-10-27 2017-10-27 Interleukin 8 (il-8) as a prognostic and predictive biomarker and compositions and vectors for use in oncolytic immunotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20165814A FI20165814A (en) 2016-10-27 2016-10-27 INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY

Publications (1)

Publication Number Publication Date
FI20165814A true FI20165814A (en) 2018-04-28

Family

ID=60569934

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20165814A FI20165814A (en) 2016-10-27 2016-10-27 INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY

Country Status (2)

Country Link
FI (1) FI20165814A (en)
WO (1) WO2018078220A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CA3013639A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN110062630A (en) 2016-12-12 2019-07-26 萨克生物研究学院 Cancer target synthesizes adenovirus and application thereof
EP3880822A1 (en) * 2018-11-12 2021-09-22 APTARION biotech AG Cxcl8 binding nucleic acids
CN111363726A (en) * 2018-12-26 2020-07-03 上海元宋生物技术有限公司 Oncolytic virus expressing interferon and application thereof
EA202192645A1 (en) * 2019-03-28 2022-01-13 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч IFN AS A PHARMACODYNAMIC MARKER FOR ONCOLYTIC THERAPY VSV-IFN-NIS
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
WO2025012635A1 (en) * 2023-07-11 2025-01-16 Theolytics Ltd Adenoviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096781A1 (en) * 2001-08-31 2003-05-22 University Of Southern California IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma
ATE527278T1 (en) 2002-12-16 2011-10-15 Genmab As HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)
US9345787B2 (en) * 2008-12-22 2016-05-24 Targovax Oy Adenoviral vectors and methods and uses related thereto
US20130323205A1 (en) * 2010-09-24 2013-12-05 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
EP2831112A1 (en) * 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
KR101458947B1 (en) 2013-03-05 2014-11-12 국립암센터 Interleukin-8 aptamers and uses thereof
KR20210084651A (en) 2013-04-18 2021-07-07 틸트 바이오세러퓨틱스 오이 Enhanced adoptive cell therapy
CN107406859A (en) 2015-03-17 2017-11-28 倾斜生物医疗公司 The oncolytic adenovirus of encoding bispecific antibody and relative method and purposes

Also Published As

Publication number Publication date
WO2018078220A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
FI20165814A (en) INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY
EP3950941A3 (en) Dnase polypeptide variants
EA201891001A1 (en) VACCINES ON THE BASIS OF NUCLEIC ACIDS AGAINST WINDSHEAD VIRUS (VZV)
MX2023001119A (en) VARIANTS OF ENZYMES AND POLINUCLEOTIDES THAT CODE THEM.
MX2018008051A (en) Beta-glucanase variants and polynucleotides encoding same.
BR112017013981A2 (en) anti-cll1-specific chimeric single-chain antigen receptors (sccars) for cancer immunotherapy
EP3741848A3 (en) Protease variants and polynucleotides encoding same
BR112016013347A2 (en) anti-il-33 neutralizing human monoclonal antibody
MX2017006216A (en) Compositions and methods of treating amyotrophic lateral sclerosis (als).
BR112017009728A2 (en) isolated antibodies, isolated nucleic acid, vector, host cell, method for producing antibody, composition, uses of an antibody and methods of treating a disorder
UA117575C2 (en) ANTIBODY WHICH SPECIFICALLY Binds to IL-17A AND ITS APPLICATION
WO2016196975A8 (en) Neutralizing antibodies to hiv-1 env and their use
MX2015016814A (en) Anti-tweakr antibodies and uses thereof.
MX2022001085A (en) HUMANIZED ANTI-C1S ANTIBODIES AND METHODS FOR USING THEM.
WO2015013388A3 (en) Anti-galectin-1 monoclonal antibodies and fragments thereof
MX2019000140A (en) Xylanase variants and polynucleotides encoding same.
MX2024009271A (en) OPTIMIZED NUCLEIC ACID ANTIBODY CONSTRUCTS.
MX2023010076A (en) Ilt7 binding molecules and methods of using the same.
PH12019502298A1 (en) Monoclonal antibody to pd-l1
EP3964575A3 (en) Alpha-amylase variants and polynucleotides encoding same
PE20190415A1 (en) HUMANIZED ANTI-BASIGIN ANTIBODIES AND THE USE OF THEM
EP4357453A3 (en) Lipase variants, polynucleotides encoding same and the use thereof
PH12018501070A1 (en) Anti-pcsk9 antibody and use thereof
MX358243B (en) Anti-vasa antibodies, and methods of production and use thereof.
MX2019005492A (en) Antibody binding to carbonic anhydrase and use thereof.

Legal Events

Date Code Title Description
FD Application lapsed